Skip to content

Evidence & methodology

How the record is sourced and how the score is derived.

A score, where shown, is formula-derived — not an editorial verdict. Read the methodology.

By the · Method: how we source and score · Last reviewed

Expert analysis

An excerpt; the full analysis opens on request.

Verdict: innovation subsidies can enrich the already well funded

Ekaterina Zaharieva's innovation portfolio presents an important public dilemma. European research can create medicines, cleaner industrial processes and more productive enterprises, yet grants and government-backed capital can also concentrate among organisations with the best administrative teams rather than the best ideas. The beneficiaries of successful programmes include researchers, patients, workers and firms creating useful technologies. Potential financial beneficiaries include venture funds, specialist consultants, universities and companies that repeatedly win grants. Taxpayers carry the risk of failed research; private shareholders may retain the upside when an innovation becomes profitable. That distribution is not inherently improper: many promising technologies require public support at an early stage. However, Zaharieva's accountability must be evaluated by additional research and valuable outcomes rather than spending volume. PROVEN: she is the European Commissioner for Startups, Research and Innovation. UNPROVEN: there is no evidence in the cited records that she took private payments or improperly awarded a particular grant.

Office, personal career and the institutional chain

Zaharieva served in Bulgaria's parliament and previously held ministerial posts involving foreign affairs, justice and regional development. She entered the European Commission in December 2024. Her responsibilities now include the European Innovation Council, European Research Council, proposed legislation concerning innovation and research mobility, and oversight of Horizon Europe research funding. These are different instruments, administered through directorates and executive bodies with their own procedures. The Commissioner proposes priorities and provides political supervision; she does not personally select every scientist receiving a competitive fellowship. The Council and European Parliament control much of the legal and budgetary framework. National universities and institutes often employ the researchers and administer project spending. A serious financial inquiry must identify the specific programme, grant decision, contracting entity, award conditions and beneficiaries before attributing either success or wrongdoing. Political visibility cannot replace an evidence chain.

The October 2026 research competitiveness argument

The Commission's October 1 news described a new assessment warning that Europe must scale research and innovation to remain competitive. A corresponding October 5 annual progress report reviews simplification and implementation under Zaharieva's portfolio. These are relevant contemporary markers, but a Commission assessment is an institutional analysis, not independent proof that every proposed subsidy will create more innovation. An economy can have excellent basic research and still struggle with manufacturing, financing or market access. Conversely, greater public research expenditure can be absorbed by weak projects if selection criteria do not reward quality. The public deserves programme evaluations showing scientific outputs, commercial adoption where appropriate, successful independent replication and benefits beyond the funded institutions. A proposal for administrative simplification should identify precisely which requirements are reduced and which fraud, safety or research-integrity protections remain.

Research grants and the selection problem

Peer-reviewed grant programmes can support work with genuine public value that private investors avoid because returns are distant or uncertain. But the application process can favour established institutions with professional grant writers, international networks and the ability to bridge funding gaps. Early-career researchers, scientists outside capital cities and smaller laboratories may be disadvantaged even when their ideas are strong. Evaluation should compare success rates by career stage, geography, institution size and field, accounting for differences in proposal quality and programme scope. Merely equalising award counts would not prove fairness; identifying barriers and measuring research merit are both necessary. Award decisions need transparent conflict-of-interest rules and independent appeal or correction routes. Zaharieva's office should resist equating a high headline acceptance rate or an expanding budget with the production of scientific breakthroughs.

Startup finance and the public-private asymmetry

The planned Trusted Investors network and support for start- and scale-ups aim to attract capital to European companies developing promising technologies. Co-investment can help firms reach manufacturing scale, retain jobs and compete in global markets. Yet a public guarantee or subsidy can leave the state carrying disproportionate downside risk while investors receive valuable participation rights. A venture-capital firm may also benefit from public endorsement even without providing a fair valuation. Every financial instrument needs disclosure of risk-sharing terms, selection standards and the handling of conflicts. An announced fund size is not the same as money committed to companies, and committed money is not necessarily cash already invested. The test is additional investment attributable to public participation and the value of products delivered, not merely the number of companies appearing in a promotional portfolio.

Science freedom and research security

A proposed European Research Area Act is meant to improve mobility of scientific knowledge, researchers and technology. Easier cross-border employment and infrastructure access can strengthen science, but security concerns arise when sensitive work or equipment has military applications. Restrictions may be justified to prevent misuse while still threatening academic freedom if applied too broadly. The Commission's implementation dialogue on attracting and retaining research talent took place on July 10, 2026, according to its current programme register. That dialogue is evidence of consultation, not proof that recruitment conditions have improved. Talent retention should be evaluated through salaries, stable contracts, career progression and access to laboratories, not a tally of conferences. A researcher should understand the legal basis and review process for a security restriction; nationality alone should not be treated as proof of wrongdoing.

Industrial research and the pressure from incumbents

The September 9, 2026 remarks on the European Innovation Act and public procurement show the overlap between research policy and industrial purchasing. Public authorities can use procurement to help bring useful technology to market, especially where the first customer is difficult to obtain. That creates a risk that specifications effectively fit one incumbent supplier or that demonstration projects become permanent subsidies without competitive results. A fair programme should allow innovative small businesses to bid and publish measurable performance criteria. Universities and companies may legitimately cooperate while retaining disclosure obligations about intellectual property, ownership and researcher interests. Announced innovation partnerships cannot be counted as working products. Audit should distinguish pilots from operational deployment, disclosed public contribution from private investment and genuine performance gains from public-relations language.

Artificial intelligence for science and concentrated computing power

Zaharieva's portfolio includes increasing AI use in research and contributing to arrangements for European AI science capacity. Shared computing and model tools could lower the cost of discovering materials or analysing biomedical data, giving smaller institutions access to tools otherwise controlled by large technology groups. But cloud providers, chip manufacturers and data-centre developers may capture much of the financing. The public interest requires accounting for electricity, long-term operating costs, intellectual-property controls and fair access. A laboratory receiving compute credits may not produce additional credible science if training and data quality are inadequate. The strongest test compares reproducible research results and access across institutions, while protecting sensitive data. Officials should resist claiming sovereignty merely because a server is physically located in Europe when supply, software and contractual control remain concentrated.

Life sciences, patients and the public return

A life-sciences strategy may help advance diagnostics, medicines and biotechnology. Research can improve health and create skilled jobs, but public support does not by itself guarantee affordable products. A profitable therapy developed with public grants may remain inaccessible to patients if licensing, pricing and reimbursement are poorly designed. At the same time, forcing an unrealistic price commitment can discourage investment in exceptionally risky projects. Policymakers should negotiate appropriate public-return terms, including publication of results, access commitments where justified and treatment of essential intellectual property. A clinical trial milestone is not proof that a medicine works safely in general practice; regulators and health systems have separate responsibilities. Zaharieva should be credited for research initiatives within her mandate, not for independent national coverage decisions or authorisations by medicines regulators.

Transparency, lobbying and accountability links

The Commission publishes the commissioner's calendar, declaration of interests and information about meetings with interested groups. In October 2026 the calendar included contact with organisations in the automotive sector and a discussion on AI and equity. Such meetings can provide valuable technical information and do not establish improper influence. However, large industrial associations often possess more capacity to influence early drafting than small laboratories or independent researchers. Investigators should compare stakeholder access, consultation input and subsequent grant eligibility rules, and seek documentary evidence before asserting causation. Factrail's linked profiles of Ursula von der Leyen (opens in a new tab), Wopke Hoekstra (opens in a new tab) and Henna Virkkunen (opens in a new tab) explain related but distinct Commission powers on priorities, climate-related economics and digital sovereignty. The links are context, not evidence of a private arrangement.

Countercase and the 2027 outcome audit

The most persuasive defence of public innovation spending is that knowledge spillovers and long horizons mean private investors systematically underfund some socially valuable research. The strongest objection is that political targets, administrative capacity and lobbying can misdirect funds toward established recipients and commercial firms that would have invested anyway. Both may be true across different programmes. A credible 2027 review should disclose awards, payments, scientific outputs, open access, subsequent private investment, follow-on product use and distribution across regions and institutions. It should measure project cancellation and fraud recovery as well as successes. Forecast leverage should not be treated as realised value, and patents should not be counted as proof of social benefit. This dossier does not allege criminal misconduct by Zaharieva. The essential question is whether the programmes produce additional, accessible knowledge and durable public gains after their full costs are counted.

Sources

Dispute a fact on this pageNamed here, or represent someone who is? Request a right of reply.